Analysts Are Buzzing About This Potential Breakthrough in Cancer Therapy

Discover why Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is gaining Wall Street’s unanimous STRONG BUY rating. From earning FDA’s Fast Track Designation to showcasing at ASCO 2023, this small biotech firm is poised to make big strides in cancer treatment. Don’t miss your chance to learn more about their promising drug trials and a potential price target of $15.00.

There’s Big Business Happening In Drug Repurposing

How Marvel Biosciences Corp. (TSXV:MRVL) is preparing to tackle multiple diseases with huge markets, by redeveloping pre-approved treatments. Sold under the name Humira, and boasting 10 approved uses, AbbVie’s adalimumabis has emerged as the best-selling drug in the world.[1] As 2023 approaches, the biotech sector is priming for when Humira officially becomes off patent, unleashing […]

How a New Sustainable Lithium Production Technology Could Save the EV Revolution

With Lithium Demand Set to Double by 2030 and Drastically Outpacing New Supply, Lithium South Development (TSXV:LIS) (OTC:LISMF) is Poised with a World-Class Project and Potentially Sector Disrupting Technology to Lead the Way to a Sustainable ‘Gold Rush’ in Argentina While lithium prices reach new highs, the lithium sector is battling a multi-front war against […]